Histone deacetylase inhibitor sodium butyrate suppresses DNA double strand break repair induced by etoposide more effectively in MCF-7 cells than in HEK293 cells

BMC Biochemistry

Volumn 16, Issue 1, 2015, Pages

  Li, Liping ^a   Sun, Youxiang ^a   Liu, Jiangqin ^a   Wu, Xiaodan ^a   Chen, Lijun ^a   Ma, Li ^a   Wu, Pengfei ^a  

^a GUANGDONG MEDICAL UNIVERSITY   (China)

Author keywords

Double strand breaks; Etoposide; HEK293; Histone deacetylase inhibitor; MCF 7; Sodium butyrate

Indexed keywords

BUTYRIC ACID; ETOPOSIDE; HISTONE H2AX; RAD51 PROTEIN; H2AFX PROTEIN, HUMAN; HISTONE; HISTONE DEACETYLASE INHIBITOR;

ARTICLE; CELL CYCLE S PHASE; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; COLONY FORMATION; CONTROLLED STUDY; CYTOTOXICITY; DNA REPAIR; DOSE RESPONSE; DOUBLE STRANDED DNA BREAK; DRUG POTENTIATION; EMBRYO; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; HEK293 CELL LINE; HUMAN; HUMAN CELL; MCF 7 CELL LINE; PROTEIN EXPRESSION; UPREGULATION; DRUG EFFECTS; MCF-7 CELL LINE; METABOLISM;

BUTYRIC ACID; CELL PROLIFERATION; DNA BREAKS, DOUBLE-STRANDED; DNA REPAIR; DRUG SYNERGISM; ETOPOSIDE; HEK293 CELLS; HISTONE DEACETYLASE INHIBITORS; HISTONES; HUMANS; MCF-7 CELLS; S PHASE;

EID: 84924204802     PISSN: None     EISSN: 14712091     Source Type: Journal    
DOI: 10.1186/s12858-014-0030-5     Document Type: Article

References (23)

1. Vashishta A, Hetman M: Inhibitors of histone deacetylases enhance neurotoxicity of DNA damage. Neuromolecular Med 2014, Epub ahead of print
2. Iwahashi S, Utsunomiya T, Imura S, Morine Y, Ikemoto T, Arakawa Y, et al. Effects of valproic acid in combination with S-1 on advanced pancreatobiliary tract cancers: clinical study phases I/II. Anticancer Res. 2014;34(9):5187-91.
3. Khabele D. The therapeutic potential of class I selective histone deacetylase inhibitors in ovarian cancer. Front Oncol. 2014;4:111.
4. Chao OS, Goodman OB Jr: Synergistic loss of prostate cancer cell viability by co-inhibition of HDAC and PARP. Mol Cancer Res 2014, Epub ahead of print
5. Lee JH, Choy ML, Ngo L, Foster SS, Marks PA. Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair. Proc Natl Acad Sci USA. 2010;107(33):14639-44.
6. Thompson LH. Recognition, signaling, and repair of DNA double-strand breaks produced by ionizing radiation in mammalian cells: The molecular choreography. Mutation Research. 2012;751(2):158-246.
7. Dong Q, Sharma S, Liu H, Chen L, Gu B, Sun X, et al. HDAC inhibitors reverse acquired radio resistance of KYSE-150R esophageal carcinoma cells by modulating Bmi-1 expression. Toxicol Lett. 2014;224(1):121-9.
8. Li L, Wang H, Yang ES, Arteaga CL, Xia F. Erlotinib attenuates homology-directed recombinational repair of chromosomal breaks in human breast cancer cells. Cancer Res. 2008;68(22):9141-6.
9. Marchion DC, Bicaku E, Daud AI, Sullivan DM, Munster PN. In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates. Mol Cancer Ther. 2005;4(12):1993-2000.
10. Chao H, Wang L, Hao J, Ni J, Chang L, Graham PH, et al. Low dose histone deacetylase inhibitor, LBH589, potentiates anticancer effect of docetaxel in epithelial ovarian cancer via PI3K/Akt pathway in vitro. Cancer Lett. 2013;329(1):17-26.
11. Thurn KT, Thomas S, Raha P, Qureshi I, Munster PN. Histone deacetylase regulation of ATM-mediated DNA damage signaling. Mol Cancer Ther. 2013;12(10):2078-87.
12. Gabrielli B, Brown M. Histone deacetylase inhibitors disrupt the mitotic spindle assembly checkpoint by targeting histone and nonhistone proteins. Adv Cancer Res. 2012;116:1-37.
13. Koprinarova M, Markovska P, Iliev I, Anachkova B, Russev G. Sodium butyrate enhances the cytotoxic effect of cisplatin by abrogating the cisplatin imposed cell cycle arrest. BMC Mol Bio. 2010;11:49.
14. Haberland M, Johnson A, Mokalled MH, Montgomery RL, Olson EN. Genetic dissection of histone deacetylase requirement in tumor cells. Proc Natl Acad Sci USA. 2009;106(19):7751-5.
15. Miller K, Tjeertes J, Coates J, Legube G, Polo S, Britton S, et al. Human HDAC1 and HDAC2 function in the DNA-damage response to promote DNA nonhomologous end-joining. Nat Struct Mol Biol. 2010;17(9):1144-51.
16. Conti C, Leo E, Eichler GS, Sordet O, Martin MM, Fan A, et al. Inhibition of histone deacetylses in cancer cells slows down replication forks, activates dormant origins, and induces DNA damage. Cancer Res. 2010;70(11):4470-80.
17. Koprinarova M, Botev P, Russev G. Histone deacetylase inhibitor sodium butyrate enhances cellular radiosensitivity by inhibiting both DNA nonhomologous end joining and homologous recombination. DNA Repair (Amst). 2011;10(9):970-7.
18. Xiao W, Graham PH, Hao J, Chang L, Ni J, Power CA, et al. Combination therapy with the histone deacetylase inhibitor LBH589 and radiation is an effective regimen for prostate cancer cells. PLoS One. 2013;8(8):e74253.
19. Tang J, Cho NW, Cui G, Manion EM, Shanbhag NM, Botuyan MV, et al. Acetylation limits 53BP1 association with damaged chromatin to promote homologous recombination. Nat Struct Mol Biol. 2013;20(3):317-25.
20. Ladd B, Ackroyd JJ, Hicks JK, Canman CE, Flanagan SA, Shewach DS. Inhibition of homologous recombination with vorinostat synergistically enhances ganciclovir cytotoxicity. DNA Repair (Amst). 2013;12(12):1114-21.
21. Kachhap SK, Rosmus N, Collis SJ, Kortenhorst MS, Wissing MD, Hedayati M, et al. Downregulation of homologous recombination DNA repair genes by HDAC inhibition in prostate cancer is mediated through the E2F1 transcription factor. Plos One. 2010;5(6):e11208.
22. Blattmann C, Oertel S, Ehemann V, Thiemann M, Huber PE, Bischof M, et al. Enhancement of radiation response in osteosarcoma and rhabdomyosarcoma cell lines by histone deacetylase inhibition. Int J Radiat Oncol Biol Phys. 2010;78(1):237-45.
23. Kuribayashi T, Ohara M, Sora S, Kubota N. Scriptaid, a novel histone deacetylase inhibitor, enhances the response of human tumor cells to radiation. Int J Mol Med. 2010;25(1):25-9.